Eli Lilly expanded its genetic‑medicine footprint with two strategic transactions: the company acquired global rights to MeiraGTx’s AAV‑AIPL1 retinal program and signed a $1.2 billion collaboration with Suzhou Sanegene Bio to advance tissue‑selective RNAi candidates for metabolic disease. The deals add late‑stage ocular gene therapy assets and RNAi delivery technology to Lilly’s pipeline and reflect big‑pharma appetites for genetic modalities and delivery platforms.